Hetero Healthcare Ltd Introduces Hetran, Pioneering a New Generation of Acid Blockers - Video

Published On 2024-06-27T12:20:59+05:30 | Updated On 17 Aug 2024 11:22 AM IST

Overview

Hetero Healthcare Ltd, one of India's leading pharmaceutical companies, has launched Vonoprazan, a new-age acid blocker, under the brand name Hetran. It is used for the treatment of gastric acid-related disorders. With this, Hetero becomes the first manufacturer-cum-marketing company to bring this product in India.

Hetran tablets containing Vonoprazan fumarate are available in two dosage strengths - 10mg and 20mg. Vonoprazan a novel potassium-competitive acid blocker (P-CAB), is approved by the DCGI for the treatment of reflux esophagitis, gastroduodenal ulcer, and duodenal ulcer. It can also be combined with antibiotics to eradicate Helicobacter pylori infections.

Unlike available therapies, the onset of action of Vonoprazan starts right from the first dose. Vonoprazan competitively and reversibly blocks the potassium binding site of H+/K+ATPase, allowing a longer duration of action. Additionally, it can be administered independently of food and has minimal drug-drug interactions.

Mr Sandeep Shastri, Executive Director, Hetero Healthcare Ltd said, “With the introduction of Vonoprazan under the brand name Hetran for the first time in India, we are dedicated to providing relief to patients suffering from gastric acid disorders. Numerous studies have shown Vonoprazan's superior efficacy in treating esophagitis and other acid-related disorders, providing rapid and sustained relief compared to conventional therapies”.

He further added, “Proton pump inhibitors fail to adequately control symptoms in up to 40% of patients with reflux diseases. We take pride in bringing this new-age acid blocker, Vonoprazan for the first time in India for the management of acid-related disorders. Hetero Healthcare Ltd is the basic manufacturer of Vonoprazan in the country”.

Hetero Healthcare Ltd, headquartered in Hyderabad, is a pharmaceutical manufacturing company that operates globally in the active pharmaceutical ingredient (API) and generic formulations businesses.

Disclaimer: This post has been published under MD Brand Connect Initiative and is sponsored by Hetero Healthcare Ltd.

Speakers

Dr. Nandita Mohan

BDS, MDS( Pedodontics and Preventive Dentistry)

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751